MEDICAMEQ - Medicamen Biotec
📢 Recent Corporate Announcements
Medicamen Biotech Limited has received a cautionary letter from the National Stock Exchange (NSE) regarding observations in its Secretarial Compliance Report for the financial year ended March 31, 2025. The communication, received on January 27, 2026, advises the company to be more diligent in adhering to SEBI Listing Regulations to prevent future lapses. The company has clarified that this regulatory warning has no quantifiable impact on its financial or operational activities. This is an administrative warning rather than a financial penalty or suspension.
- NSE issued a cautionary letter on January 27, 2026, following secretarial audit observations.
- The observations pertain to the Annual Secretarial Compliance Report for the financial year ended March 31, 2025.
- The company has been advised to be careful in the future to avoid recurrence of such compliance lapses.
- Management confirms there is zero impact on the company's financials, operations, or other activities.
Medicamen Biotech Limited has issued a corrigendum regarding the retirement of two Independent Directors, Mr. Harish Pande and Mr. Arun Kumar. The company clarified that their term concludes on February 26, 2026, rather than the February 13, 2026 date previously reported. This correction follows a clerical error in the initial intimation. The update ensures regulatory compliance and accurate record-keeping regarding board composition.
- Retirement date for Independent Directors Mr. Harish Pande and Mr. Arun Kumar corrected to Feb 26, 2026.
- Initial announcement dated Feb 13, 2026, cited an incorrect retirement date due to a clerical error.
- The directors will officially cease their roles at the close of business on February 26, 2026.
Medicamen Biotech Limited has announced the completion of the terms of two Independent Directors, Mr. Harish Pande and Mr. Arun Kumar, effective February 13, 2026. Both directors have consequently stepped down from their positions in the Audit, Nomination & Remuneration, and Risk Management committees. To ensure a smooth transition, the company had previously appointed Mr. Sham Goel and Mr. Shaival Saurabh as Independent Directors in August 2025. Mr. Sham Goel will now assume the role of Chairman for the Audit and CSR Committees, maintaining continuity in the company's governance structure.
- Mr. Harish Pande and Mr. Arun Kumar completed their tenures as Independent Directors on February 13, 2026.
- The outgoing directors ceased to be members/chairpersons of five key board committees including Audit and Risk Management.
- Successors Mr. Sham Goel and Mr. Shaival Saurabh were pre-appointed in August 2025 and approved by shareholders in September 2025.
- Mr. Sham Goel is designated as the new Chairman of the Audit Committee and CSR Committee effective February 13, 2026.
Medicamen Biotech reported a consolidated net profit of ₹1.63 crore for the quarter ended December 31, 2025, representing a 19.1% decline from ₹2.02 crore in the same quarter last year. Total revenue saw a marginal increase of 2.6% year-on-year, reaching ₹47.04 crore. Despite the quarterly dip, the nine-month performance remains positive with a net profit of ₹5.31 crore compared to ₹4.69 crore in the previous year. The company also announced the cessation of two independent directors following the completion of their tenures.
- Consolidated Total Revenue grew slightly to ₹47.04 crore in Q3 FY26 from ₹45.83 crore in Q3 FY25.
- Consolidated Net Profit for the quarter fell to ₹1.63 crore, down from ₹2.02 crore in the previous year.
- Earnings Per Share (EPS) decreased significantly to ₹1.21 from ₹2.30 in the corresponding quarter.
- Nine-month consolidated net profit showed improvement at ₹5.31 crore versus ₹4.69 crore YoY.
- Independent Directors Harish Pande and Arun Kumar completed their 10-year tenures effective February 13, 2026.
Medicamen Biotech reported a consolidated total revenue of ₹47.04 crore for Q3 FY26, representing a modest 2.6% growth compared to ₹45.83 crore in the same quarter last year. However, consolidated net profit for the quarter declined by 19.1% YoY to ₹1.63 crore, down from ₹2.02 crore, as subsidiary performance weighed on the bottom line. On a standalone basis, the company performed better with a net profit of ₹2.59 crore. The company also announced the retirement of two independent directors and the subsequent reconstitution of key board committees.
- Consolidated Total Revenue increased by 2.6% YoY to ₹47.04 crore in Q3 FY26.
- Consolidated Net Profit declined 19.1% YoY to ₹1.63 crore from ₹2.02 crore.
- Standalone Net Profit grew slightly by 2.7% YoY to ₹2.59 crore.
- Consolidated EPS for the quarter dropped to ₹1.21 from ₹2.30 in the previous year.
- Independent Directors Mr. Harish Pande and Mr. Arun Kumar retired after completing two 5-year terms.
Medicamen Biotech Limited has submitted its compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. This document covers the quarter and nine-month period ending December 31, 2025. The company confirms that securities received for dematerialization were processed, and physical certificates were mutilated and cancelled within the mandated 30-day timeframe. This is a standard regulatory filing ensuring the integrity of shareholding records and compliance with depository norms.
- Compliance certificate submitted for the quarter and nine months ended December 31, 2025.
- Confirms securities dematerialized or rematerialized are listed on BSE and NSE.
- Physical certificates were mutilated and cancelled within 30 days of receipt as per SEBI norms.
- The name of the depository has been substituted in records as the registered owner for dematerialized shares.
Medicamen Biotech Limited has successfully obtained product registration approval for Paracetamol from the Danish Medicine Authority. This approval was secured in collaboration with XGX Pharma, Denmark, marking a significant step into the European Union market. The registration validates the company's adherence to stringent EU manufacturing and quality standards. This development is expected to enhance the company's export capabilities and revenue potential within regulated international markets.
- Received EU approval for Paracetamol product registration from the Danish Medicine Authority.
- Collaborated with XGX Pharma, Denmark, to facilitate the registration process.
- Demonstrates compliance with high-level European pharmaceutical regulatory standards.
- Strengthens the company's presence and growth prospects in the European market.
Financial Performance
Revenue Growth by Segment
The company achieved a 28% YoY growth in operating income, reaching INR 179.3 Cr in FY24 compared to INR 140.8 Cr in FY23. Growth is primarily driven by the core formulations segment, while the oncology segment, which started commercial production in January 2022, is yet to reach breakeven, currently weighing on overall profitability.
Geographic Revenue Split
Africa is the dominant region, contributing approximately 70% of total sales. The remaining 30% is derived from the domestic Indian market, including government sector contracts. The company is actively planning expansion into European and USA markets over the medium term to diversify this concentration.
Profitability Margins
Operating margins declined significantly from 18.35% in FY23 to 13.1% in FY24. This 525 basis point drop is attributed to the oncology segment's gestation period. Net Profit After Tax (PAT) fell from INR 14.73 Cr (10.45% margin) in FY23 to INR 9.49 Cr (5.34% margin) in FY24.
EBITDA Margin
Operating EBITDA margin stood at 13.1% for FY24. Management expects margins to recover to the 14-15% range in FY25 as the oncology segment achieves breakeven and capacity utilization improves at the Haridwar plant.
Capital Expenditure
The company has completed major expansions including a dedicated Oncology Formulation Plant at Haridwar and capacity expansion at the Bhiwadi plant. Future growth is expected to be supported by the absence of major debt-funded capex, focusing instead on modernization of the Bhiwadi plant to meet EU standards.
Credit Rating & Borrowing
CRISIL reaffirmed ratings at 'BBB-/Stable' for long-term and 'A3' for short-term facilities. Interest coverage remains robust at 5.59x to 6.18x, though it declined from 7.90x in FY23 due to lower operating profits.
Operational Drivers
Raw Materials
Formulations are based on Betalactum and Non-Betalactum drug bases. Specific API names are not disclosed, but these chemical bases represent the primary input cost for the company's tablet, capsule, and injection lines.
Import Sources
Not specifically disclosed in the documents, though the company operates manufacturing facilities in Bhiwadi (Rajasthan) and Haridwar (Uttarakhand).
Capacity Expansion
Current operations include a US-FDA approved Oncology plant in Haridwar and an EU GMP (Greece) approved Bhiwadi plant. The company is currently modernizing the Bhiwadi facility to maintain EU compatibility and has applied for desktop approval in Australia.
Raw Material Costs
Not disclosed as a specific percentage of revenue, but the company manages commodity price risk and foreign exchange risk through its Risk Management Committee to mitigate input cost volatility.
Manufacturing Efficiency
Efficiency is currently impacted by the oncology segment's sub-optimal utilization. Breakeven in this segment is the primary target for FY25 to restore group-level manufacturing efficiency.
Logistics & Distribution
The company launched Medicamen Lifesciences, a subsidiary with a team of 110 personnel, specifically to handle domestic distribution and marketing for Cardio-Vascular, diabetic, and pain management products.
Strategic Growth
Expected Growth Rate
11-15%
Growth Strategy
Growth will be achieved by scaling the oncology segment to breakeven in FY25, entering the US market following US-FDA approval, and expanding the domestic footprint through the Medicamen Lifesciences subsidiary. The company has already filed its first ANDA with the US-FDA for Bortezomib injection (3.5mg).
Products & Services
Oncology formulations (including Bortezomib injections), Betalactum and Non-Betalactum drugs, Cardio-Vascular (CVD) medications, diabetic treatments, and pain management products.
Brand Portfolio
Medicamen, Medicamen Lifesciences (subsidiary), Shivalik Rasayan Ltd (Promoter Group).
New Products/Services
New product launches are focused on the Cardio-Vascular and Diabetic (CVD) segments and Pain Management through the new domestic distribution team.
Market Expansion
Targeting entry into the USA and European countries over the medium term. Currently seeking desktop approval in Australia and leveraging existing EU GMP certification for Bhiwadi.
Strategic Alliances
The company is 41.6% owned by Shivalik Rasayan Ltd, which provides strong promoter backing and industry linkages.
External Factors
Industry Trends
The pharmaceutical industry is shifting toward specialized oncology and chronic therapies (CVD/Diabetes). Medicamen is positioning itself by moving from general formulations to US-FDA approved oncology manufacturing.
Competitive Landscape
Competes with other formulation manufacturers in the domestic government tender business and international generic players in the African market.
Competitive Moat
The company's moat is built on its 30-year track record, US-FDA/EU GMP certified facilities, and a specialized oncology plant which acts as a high-entry-barrier asset.
Macro Economic Sensitivity
Highly sensitive to African economic stability and shipping logistics, as 70% of revenue is tied to this geography.
Consumer Behavior
Increasing demand for affordable oncology and chronic disease treatments in emerging markets (Africa) and regulated markets (USA/EU).
Geopolitical Risks
Trade barriers or shipping disruptions in the Africa-India corridor represent a major risk to the 70% revenue base.
Regulatory & Governance
Industry Regulations
Operations are strictly governed by US-FDA standards for the Haridwar plant and EU GMP standards for the Bhiwadi plant. Compliance with SEBI Listing Regulations and the Companies Act 2013 is maintained for corporate governance.
Environmental Compliance
The Risk Management Committee is tasked with overseeing ESG-related risks and sustainability frameworks.
Taxation Policy Impact
Not specifically disclosed, but the company maintains a 10% dividend payout policy relative to paid-up capital.
Legal Contingencies
No specific pending court cases or case values in INR were disclosed in the provided documents.
Risk Analysis
Key Uncertainties
The primary uncertainty is the timeline for the oncology segment to reach full capacity and breakeven, which currently impacts group margins by approximately 5%.
Geographic Concentration Risk
High concentration risk with 70% of revenue derived from Africa.
Third Party Dependencies
Dependency on shipping lines for African exports is a critical bottleneck, causing GCA to stretch to 357 days.
Technology Obsolescence Risk
The company is mitigating technology risk by modernizing its Bhiwadi plant to meet evolving EU standards.
Credit & Counterparty Risk
Receivables are generally secured by Letters of Credit for international sales, reducing the risk of bad debts despite the long 103-day collection cycle.